BACKGROUND: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart failure have not yet shown improved clinical outcomes. We tested the hypothesis that the interleukin-1β inhibitor canakinumab would prevent hospitalization for heart failure (HHF) and the composite of HHF or heart failure-related mortality.
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I
nflammation accompanies the clinical syndrome of heart failure (HF). [1] [2] [3] [4] [5] [6] The concentrations of interleukin (IL)-1β and other inflammatory cytokines increase as HF worsens, 2 and both IL-6 and C-reactive protein concentrations predict death and correlate with exercise capacity in patients with HF. 3 Subsequent experimental studies demonstrated that expression of IL-1β, tumor necrosis factor (TNF)-α, and other cytokines leads to changes in nitric oxide production, as well as alterations in myocyte contractility and reversible left ventricular dysfunction and remodeling. [7] [8] [9] These observations spurred interest in anti-inflammatory therapies for the prevention or treatment of HF. Preclinical trials of etanercept and infliximab, 2 TNF inhibitors, suggested improvements in left ventricular function and 6-minute walk distance. 10, 11 However, subsequent large randomized trials of patients with established HF failed to reduce HF or increased the risk of death. 12, 13 The intervening years have yielded improved understanding of inflammatory signaling in myocardial biology and the development of left ventricular dysfunction. 14 In particular, experimental studies have demonstrated that myocardial response to injury and repair involves activation of nuclear factor-κB and downstream activation of the NOD-like receptor pyrin-3 inflammasome, IL-1β, and IL-18. 15 A number of small randomized trials have tested whether anakinra, an IL-1 receptor antagonist, 16, 17 improves aerobic capacity. No significant differences were observed between anakinra-and placebo-treated patients. 17 No data inform whether IL-1 inhibition can prevent clinical outcomes such as hospitalization for HF (HHF) or HF-related mortality. A prespecified exploratory analysis of the recently reported CANTOS study (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) specifically addressed whether IL-1β inhibition with canakinumab would improve HF outcomes. In addition, the enrollment criteria for CANTOS resulted in the selection of patients at increased risk for HF by including those with both prior myocardial infarction (MI) and an elevated high-sensitivity C-reactive protein (hsCRP). 18 
METHODS
Study Design and Participants
CANTOS randomized 10 061 patients with prior MI and hsCRP ≥2 mg/L to canakinumab 50, 150, or 300 mg or placebo given once every 3 months subcutaneously. Before randomization, participants were asked if they had a history of HF. This analysis included all patients regardless of history of baseline history of HF, although we repeated the analysis after stratifying by baseline history of HF. The protocol was reviewed and approved by the responsible institutional review board in all participating centers. The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Procedures
Patients enrolled in CANTOS had in-person visits with study staff at months 1.5 and 3 and every 3 months thereafter. Patients were asked about any hospitalizations since the most recent clinic visit, including HHF. Canakinumab or placebo was administered by subcutaneous injection at the time of each study visit. Baseline and 3-month assessments of hsCRP and IL-6 were used to define baseline and on-treatment hsCRP and IL-6 concentrations, respectively.
End Point Ascertainment and Adjudication
Evaluating the effects of canakinumab on HF was a prespecified exploratory end point of CANTOS. For this analysis, we focused on centrally validated HHF and HF-related mortality. HHF was reported by the local CANTOS investigator via a structured event report form. For patients admitted to the hospital with HF, investigators were asked to report patient symptoms (dyspnea, decreasing exercise tolerance, orthopnea, paroxysmal nocturnal dyspnea, or other symptoms), signs (rapid weight gain, rales on pulmonary examination, peripheral edema, weight gain, or other signs), laboratory abnormalities (radiological signs of HF, abnormalities in B-type natriuretic peptide), and therapeutic intensification
Clinical Perspective
What Is New?
• Subclinical inflammation is known to be associated with an increased risk of heart failure and with a worse prognosis for those with established heart failure.
• In this study, a randomized placebo-controlled trial of the monoclonal antibody to interleukin-1β canakinumab, we found a dose-dependent reduction in the risk of hospitalization for heart failure among those randomly allocated to active therapy. • This study represents the first time a targeted anti-inflammatory therapy has reduced hospitalization for heart failure in at-risk patients with a history of myocardial infarction and ongoing subclinical inflammation.
What Are the Clinical Implications?
• The results presented here are exploratory and hypothesis generating but nonetheless represent the first large-scale evidence indicating that interleukin-1-targeted therapy may have a role in preventing hospitalization for heart failure and heart failure-related mortality.
• Interleukin-1β inhibition offers a mechanistically distinct and novel approach to treating heart failure and may offer benefits to patients already being treated with established therapies. 19 Alternatively, a patient could have 1 symptom, 1 sign plus 1 laboratory abnormality, and 1 therapeutic intensification. 19 Reported cases of HF that did not meet these criteria were not validated. In total, CANTOS collected 1018 reported HHF events in 602 individuals. Application of the above criteria validated 592 of the 1018 reported HHF events (58%). The 592 events occurred in a total of 385 unique patients enrolled in CANTOS. A CONSORT (Consolidated Standards for Reporting Trials) diagram for HHF validation is presented in Figure I in the onlineonly Data Supplement. The time to the first HHF in each of those 385 unique patients was the primary outcome of interest for this analysis.
For this analysis, we also assessed the effect of canakinumab on the composite end point of the time to the first occurrence of an HHF or HF-related death. All deaths were centrally adjudicated and classified according to cause, including HF/cardiogenic shock, by a Clinical End Points Committee of cardiologists blinded to study drug allocation. In addition, on an a priori basis, we also elected to present the effect of canakinumab on the composite outcome of HHF plus cardiovascular death, HHF plus all-cause mortality, and the composite outcome of HHF, nonfatal MI, nonfatal stroke, unstable angina requiring unplanned coronary revascularization, or all-cause mortality.
Statistical Analysis
Baseline characteristics of the study population, stratified by the occurrence of HHF during follow-up, were compared by use of χ 2 tests for categorical variables and the Wilcoxon rank-sum test for continuous variables.
Exploratory analyses sought to replicate previously published associations between baseline concentrations of inflammatory biomarkers (hsCRP and IL-6) and the occurrence of HHF during the trial follow-up period. 20 We divided baseline hsCRP and IL-6 concentrations into increasing tertiles and calculated the risk of future HHF in Cox proportional hazards models after adjusting for age, sex, race, and randomized treatment allocation (model 1) and after further adjustment for diabetes mellitus, hypertension, body mass index, type of qualifying MI, history of coronary artery bypass graft surgery, aspirin, baseline low-density lipoprotein cholesterol, baseline estimated glomerular filtration rate, and baseline history of HF (model 2). Of the 10 061 patients randomized in CANTOS, 10 054 and 5058 had baseline concentrations of hsCRP and IL-6 available, respectively.
The time to the first HHF episode for the 385 unique patients with at least 1 episode of HHF was the primary outcome variable. Our primary analysis included all patients regardless of history of baseline history of HF, although we repeated the analysis after stratifying by baseline history of HF. We compared unadjusted incidence rates of HHF, HHF plus HF-related mortality, HHF plus cardiovascular mortality, HHF plus all-cause mortality, and the composite of HHF, MI, stroke, unstable angina requiring unplanned coronary revascularization, or all-cause mortality in the placebo and 50, 150, and 300 mg canakinumab groups. All incidence rates are calculated on the basis of person-time of observation, and patients were censored at death, loss to follow-up, or the end of the trial. Kaplan-Meier graphs and unadjusted log-rank P values tested for differences between randomly allocated treatment groups. We used unadjusted Cox proportional hazards to calculate the risk of HHF and the expanded composite end points among those randomly allocated to each of the canakinumab doses versus placebo. We conducted 2 sensitivity analyses to account for the competing risk of the CANTOS primary end point (a composite of nonfatal MI, nonfatal stroke, or cardiovascular death) or the competing risk of all-cause mortality. We tested the adequacy of the proportional hazards assumption in Cox regression models using methods derived from the cumulative sums of martingale residuals over follow-up times. 21 To address the question of whether inflammation reduction was related to the effects of canakinumab on HHF or to the composite outcomes noted above, we used the on-treatment hsCRP concentration 3 months after randomization to define whether a patient had achieved the prespecified on-treatment threshold of interest (<2 mg/L). In these analyses, we adjusted for covariates known from prior analysis 22, 23 to be related to on-treatment hsCRP concentrations, including age, sex, race, diabetes mellitus, hypertension, body mass index, type of qualifying MI, history of coronary artery bypass graft surgery, aspirin use, baseline hsCRP, baseline low-density lipoprotein cholesterol, baseline estimated glomerular filtration rate, and baseline history of chronic HF. All P values are 2-sided.
RESULTS
CANTOS randomized 10 061 patients. Over a median follow-up time of 3.7 years, we observed at least 1 episode of HHF in 385 unique individuals. Patients with at least 1 episode of HHF were older, had higher body mass index, and more likely had diabetes mellitus, hypertension, and prior coronary bypass surgery (Table 1) . Those who had HHF during follow-up had higher median (quartile 1, 3) baseline concentrations of hsCRP and IL-6 than those who did not. Among patients with HHF during the course of the trial, ≈60% had a history of HF at baseline. In contrast, among those who did not have an episode of HHF during the trial, 20% had a history of HF at baseline.
Baseline concentrations of hsCRP and IL-6 were associated with HHF (Figures II and III in the online-only Data Supplement). This relationship persisted after adjustment for an array of potential confounders, with individuals who had baseline hsCRP concentrations in the highest tertile at ≈1.9 times the risk of HHF compared with those with hsCRP concentrations in the lowest tertile during the course of the trial (hazard ratio [HR], 1.90; 95% CI, 1.45-2.48; Table I in the onlineonly Data Supplement). Those in the highest compared with the lowest tertile of IL-6 had similarly elevated risk (HR, 2.16; 95% CI, 1.47-3.18; Table I in the online-only Data Supplement).
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The incidence rates per 100 person-years of a first episode of HHF were 1.12 in the placebo group and 1.17 (50 mg), 0.96 (150 mg), and 0.85 (300 mg) in the canakinumab groups ( Table 2 ). The cumulative incidence of HHF, stratified by randomly allocated treatment group, is displayed in Figure 1A . The unadjusted HRs for HHF with each dose of canakinumab compared with placebo were 1.04 (95% CI, 0.79-1.36) for 50 mg, 0.86 (95% CI, 0.65-1.13) for 150 mg, and 0.76 (95% CI, 0.57-1.01) for 300 mg (P for CABG indicates coronary artery bypass graft surgery; CANTOS, Canakinumab Anti-Inflammatory Thrombosis Outcomes Study; eGFR, estimated glomerular filtration rate; HbA 1c , hemoglobin A 1c ; HDL, high-density lipoprotein; HF, heart failure; HHF, hospitalization for heart failure; hsCRP, high-sensitivity C-reactive protein; IL, interleukin; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction. trend=0.025; Table 2 ). No individual dose significantly reduced the rate of either the primary or secondary end point. In sensitivity analyses adjusted for the competing risk of the trial primary end point (a composite of nonfatal MI, nonfatal stroke, or cardiovascular mortality; Table II in the online-only Data Supplement) or the competing risk of all-cause mortality, there were no substantial changes in our estimates of the effect of canakinumab on HHF. The suggestion of a timevarying effect on HHF observed in Figure 1 was supported by statistically significant evidence of a violation of the proportional hazards assumption (P=0.03). When we analyzed HHF occurrence before the median event time of 1.7 years separately from those that occurred after the median event time, we observed no significant reduction in HHF risk for the early events, followed by a reduced risk of HHF with randomly allocated 300 mg canakinumab for the later events (Table  III in the online-only Data Supplement).
We observed a similar dose-dependent reduction in the risk of the composite outcome of HHF or HF-related mortality ( Figure 1B) . Specifically, the unadjusted HRs for HHF or HF-related mortality were 1.00 (95% CI, 0.78-1.30) for 50 mg, 0.87 (95% CI, 0.67-1.12) for 150 mg, and 0.78 (95% CI, 0.60-1.01) for 300 mg (P for trend=0.037; Table 2 ). Similar dose-dependent reductions in the composite of HHF or cardiovascular death (Figure 2A ), the composite of HHF or all-cause mortality (data not shown), and the composite of HHF, nonfatal MI, nonfatal stroke, unstable angina requiring unplanned coronary revascularization, or all-cause mortality ( Figure 2B ) were seen with random allocation to canakinumab compared with placebo (Table 2) .
Among patients with a history of HF at trial entry, the incidence rates of HHF events per 100 person-years were 3.28 (placebo), 3.61 (50 mg canakinumab), 3.26 (150 mg canakinumab), and 2.44 (300 mg canakinumab; Table 3 ). Among patients without a history of HHF at trial entry, the incidence rates of new HHF events per 100 person-years were 0.59 (placebo), 0.60 (50 mg), 0.43 (150 mg), and 0.42 (300 mg). We again observed dose-dependent reductions in the risk of HHF with in- 
creased doses of canakinumab that were similar in direction and magnitude for patients with and without a history of HF at baseline (Table 3) . Patients randomly allocated to canakinumab who achieved on-treatment hsCRP concentrations <2 mg/L, regardless of dose, had significant reductions in HHF, HHF or HF-related mortality, HHF or all-cause mortality, or HHF, major adverse cardiac events plus, or all-cause mortality, whereas those with on-treatment hsCRP concentrations ≥2 mg/L did not (Figure 3 ). For example, after adjustment for potential confounders, including age, sex, race, diabetes mellitus, hypertension, body mass index, type of qualifying MI, history of coronary artery bypass graft surgery, aspirin use, baseline hsCRP, 
baseline low-density lipoprotein cholesterol, baseline estimated glomerular filtration rate, and baseline history of chronic HF, patients who achieved hsCRP <2 mg/L had a 38% reduction in the relative risk of HHF compared with those receiving placebo (HR, 0.62; 95% CI, 0.47-0.81), whereas those with on-treatment hsCRP concentrations ≥2 mg/L did not (HR, 1.03; 95% CI, 0.81-1.31; Figure 3 and Table IV in the online-only Data Supplement). For those assigned to placebo who achieved an hsCRP <2 mg/L, the risk of HHF was not significantly different from that of those in the placebo group who had an achieved hsCRP ≥2 mg/L. Specifically, the HR of HHF was 0.93 (95% CI, 0.59-1.49).
Patients randomly allocated to canakinumab who achieved hsCRP concentrations <2.0 mg/L had reductions in the composite outcomes of HHF or HF-related mortality, HHF or all-cause mortality, and HHF, nonfatal MI, nonfatal stroke, unstable angina requiring unplanned coronary revascularization, or all-cause mortality (Figure 3 and Table IV in the online-only Data Supplement). These effects among canakinumab-treated patients persisted when analyzed by alternative on-treatment hsCRP HF indicates heart failure; HHF, hospitalization for heart failure; and HR, hazard ratio. 
DISCUSSION
These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an IL-1β inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or HF-related mortality in a population of patients with prior MI and elevations in hsCRP. This study provides evidence that baseline concentrations of the inflammatory biomarkers hsCRP and IL-6 are independently associated with future HHF. Although no single dose of canakinumab was significantly different from placebo, inflammation inhibition with canakinumab was associated with a significant dose-dependent trend in reduced rates of HHF and the composite of HHF or HF-related mortality. The effect of canakinumab on HHF applied to those with or without a history of HF. Canakinumab consistently reduced composite end points that included HHF such as HHF or all-cause mortality, or the composite of HHF, MI, stroke, coronary revascularization, or all-cause mortality. Those in whom canakinumab produced inflammation reduction evidenced by achieving on-treatment hsCRP concentrations <2 mg/L showed substantial risk reductions in these composite end points. These data have both scientific and clinical importance for a number of reasons. First, considerable experimental and human biomarker data have long pointed to the involvement of innate immunity in propagating key elements of myocardial dysfunction, and patients with advanced HF have elevated markers of inflammation. [1] [2] [3] 9, 14, 24, 25 The innate immune system, including the NOD-like receptor pyrin-3 inflammasome, contributes importantly to cardiac remodeling after ischemic injury, leading to the production of active IL-1β and to inflammatory cell accumulation in the myocardium. 15, 26 Experimental studies suggest that IL-1β has deleterious but reversible effects on myocardial energetics, β-adrenergic signaling, and contractility. 7, 9, 24, 25, 27 Age-dependent expansion of clones of hematopoietic cells that bear mutations that confer a heightened risk of cardiovascular disease occurs fairly commonly. 28, 29 Mouse experiments have shown that the most common mutation seen in that disorder (Tet2) may impair cardiac function and remodeling in a mouse model of HF through enhanced IL-1β expression and activation of the NOD-like receptor pyrin-3 inflammasome. 30 The present results suggest that among the proinflammatory cytokines elevated in patients with HF, IL-1β plays a causal role rather than merely serving as a biomarker of ongoing inflammation.
Our study differed from previously published randomized controlled trials of infliximab and etanercept by specifically targeting IL-1β, rather than TNF-α, and because CANTOS did not specifically enroll patients with established HF. Therefore, the rate of HHF in our trial was lower than that observed in prior studies of TNF-α. Although pilot randomized trials of etanercept, an inhibitor of TNF-α, led to improvements in left ventricular function, quality of life, and 6-minute walk distance, 10 ,11 a larger trial of infliximab suggested a higher risk of death among those randomized to the higher dose of active therapy. Studies of etanercept were halted early because of a lack of benefit for patients with established New York Heart Association class II to IV HF. 12, 13 The exploratory data presented provide further support for targeting IL-1β to reduce the morbidity and mortality associated with HF, a clinical syndrome of increasing prevalence and importance. Current therapy for HF focuses on decongestion with diuretics and modification of the neurohormonal pathways, the activation of which accompanies HF, but low blood pressure and azotemia often limit these therapies. The data presented here are from a population with high rates of renin-angiotensin-aldosterone system antagonist use and high rates of β-blocker use. IL-1β inhibition offers a mechanistically distinct and novel approach to therapy that leads to no clinically significant alterations in blood pressure and does not aggravate renal dysfunction. 31 The data presented here do not provide a definitive test of the hypothesis that IL-1β inhibition improves outcomes in HF, but they do suggest that targeting the NOD-like receptor pyrin-3 inflammasome and IL-1β pathway in HF merits pursuit in future clinical trials focused on an HF population.
Strengths and Limitations
CANTOS was a large randomized double-blind placebo-controlled study, which minimizes the chance that our observation results from confounding. The size and design of this study reinforce the main observation of a significant dose-related trend toward a reduced rate of HHF for patients randomly allocated to canakinumab in this analysis. We centrally validated all episodes of HHF by applying a consistent, rigorous, specific definition of what constituted HHF episodes. A number of limitations bear mentioning. Although we know that all patients in CANTOS had a history of MI, we do not know their ejection fraction or natriuretic peptide concentrations at the time of randomization or at the time of HHF. Thus, we are unable to differentiate the effects of canakinumab on HF with reduced compared with preserved left ventricular function. We acknowledge
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that although no single dose of canakinumab compared with placebo demonstrated a statistically significant reduction in the risk of HHF, the trend across all 3 doses was statistically significant. Although assessing the effect of canakinumab on HF was a prespecified aim of CANTOS, the data presented here should nonetheless be considered hypothesis generating. The achieved hsCRP on-treatment analyses are after randomization and thus subject to confounding. However, we adjust for covariates that we know from analyses of the trial primary and secondary end points are related to on-treatment hsCRP, but we were unable to perform a causal inference analysis because the number of HHF end points was too small. Nonetheless, we know from 2 prior studies with a larger number of end points that the approach used here is valid.
22,23
CONCLUSIONS
These data suggest a therapeutic pathway of inflammation reduction that merits further scientific and clinical exploration as a novel means to reduce HHF in selected patients. Readmissions for HF present an enormous human challenge and drain on healthcare resources that urgently demand new approaches. The present data, although exploratory and hypothesis generating, represent the first large-scale evidence indicating that IL-1-targeted therapy may have a role in HF.
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